Indeed, AR9281 and GSK2256294 are new sEH inhibitors that are being tested in clinical trials to assess their efficacy and safety for the treatment of hypertension and other cardiovascular diseases [30,31]. Here, EPHX2 is linked to hypertensive disorder.